NCT05390749View on ClinicalTrials.gov

Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2026

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

Orelabrutinib

Orelabrutinib will be given as 150mg orally d1-d21 for 6 cycles,every 21 days for 1 cycle.

DRUG

Pomalidomide

Pomalidomide will be given as 4mg d1-d14 for 4 cycles,every 21 days for 1 cycle.

DRUG

Rituximab

Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol

DRUG

Methotrexate

methotrexate 3.5g/m2 civ d1/cycle5-6

Trial Locations (3)

100070

RECRUITING

Beijing TianTan Hospital, Beijing

100500

RECRUITING

Sanbo Brain Hospital Capital Medical University, Beijing

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Tiantan Hospital

OTHER

collaborator

Capital Medical University

OTHER

lead

Peking Union Medical College Hospital

OTHER